Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04567160
Other study ID # 2021-2343
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date October 1, 2020
Est. completion date March 17, 2022

Study information

Verified date December 2023
Source Ciusss de L'Est de l'Île de Montréal
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this prospective randomized controlled study is to compare the analgesic properties of propofol and sevoflurane using variation of the NOL index and standard monitoring (Heart Rate and Mean Arterial Blood Pressure) when patients under general anaesthesia with either agents are subjected to a standardized painful stimulus (a tetanic stimulation over the ulnar nerve at 70 mA, 100 Hz for 30 seconds).


Description:

This study proposes a research design that compare the analgesic properties of two commonly used agents for induction and maintenance of the hypnotic component of anesthesia: propofol versus sevoflurane. Using the NOL index to quantitatively monitor nociception, it is expected to see a difference in response to a standardized electrical and tetanic stimulus during general anesthesia maintained with either agents. Hypothesis is that magnitude of the variation and/or the value of the NOL Index following a standardized nociceptive stimulus is lower when general anesthesia is based on propofol rather than on sevoflurane. Induction of general anesthesia will differ depending in which group the patient belongs. In the propofol group, general anesthesia will be induced using target-controlled infusion (TCI) of propofol and remifentanil. In the sevoflurane group, induction of general anesthesia will be carried out by spontaneous breathing through a mask while progressively opening up the dial of the sevoflurane vaporizer up to 8%. Like in the propofol group, target-controlled infusion of remifentanil is simultaneously started to reach an initial target predicted effect-site concentration of 3 ng/mL. Vaporizer is adjusted when gas equilibration reaches the patient-specific concentration 1.0 MAC of sevoflurane. At this point, noxious stimulation will be delayed at least 10 minutes after TCI remifentanil is paused to allow for the remifentanil to be cleared out and to ensure brain-alveolar equilibration of sevoflurane (sevoflurane group). Measurements of the NOL Index, BIS, HR and MAP start 1 minute before applying noxious stimulus (prestimulation period). Means of the data collected during that period will constitute the basal values for NOL and HR before stimulation. After this stand-by period, electric stimulation is applied. This will consist in a standardized tetanic stimulation to the ulnar nerve of the non-dominant forearm delivered by a routine nerve stimulator at a frequency of 100 Hz and a current of 70 mA for a duration of 30 seconds. Measurements of the NOL Index, BIS, HR and MAP will continue during 3 minutes after (poststimulation period). This window of recording has to be free of any other external stimulation as it could produce noise disturbance on recorded values. After the stimulation, all the monitors will be used to guide intraoperative administration of hypnotic agents and analgesics. Total consumption of hypnotics and opioids will be recorded for the duration of surgery. Postoperative assessment of pain and opioid consumption will be done in post anesthesia care unit as exploratory outcomes.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date March 17, 2022
Est. primary completion date March 17, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - ASA status I, II or III - Age 18 years or older - Elective surgery under general anesthesia. - Good understanding of English or French language Non-inclusion Criteria - Ongoing Coronary artery disease - Patients with non-regular sinus cardiac rhythm, implanted pacemakers, prescribed antimuscarinic agents, a2-adrenergic agonists, ß1-adrenergic antagonists and antiarrhythmic agents - Emergent surgery - Pregnancy/lactation - Preoperative hemodynamic disturbance - Central nervous system disorder (neurologic/head trauma/uncontrolled epileptic seizures) - Patient refusal - Drug or alcohol abuse within the last 6 months - Chronic use of psychoactive drugs - Pre-operative chronic opioid use or chronic pain, equivalent to oxycodone 20mg per oral, per day for more than 6 weeks - History of psychiatric diseases or psychological problems - Allergy or intolerance to any of the study drugs Exclusion Criteria: - Unexpected difficult airway requesting excessive, possibly painful airway manipulations. - Intraoperative unexpected complications requiring strong hemodynamic support (transfusions, vasopressors, inotropes)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Propofol
In the propofol group, general anesthesia will be induced using target-controlled infusion (TCI) of propofol and remifentanil. Marsh pharmacokinetic model will be used to set the initial target predicted effect-site concentration of propofol at 3.0 mcg/ml in flash mode. Simultaneously, target-controlled infusion of remifentanil will be started to reach an initial target predicted effect-site concentration of 3 ng/mL using the Minto pharmacokinetic model. After tracheal intubation, TCI of remifentanil is paused.
Sevoflurane
In the sevoflurane group, induction of general anesthesia will be carried out by spontaneous breathing through a mask while progressively opening up the dial of the sevoflurane vaporizer up to 8%. Like in the propofol group, target-controlled infusion of remifentanil is simultaneously started to reach an initial target predicted effect-site concentration of 3 ng/mL. Vaporizer is adjusted when gas equilibration reaches the patient-specific concentration 1.0 MAC of sevoflurane. After tracheal intubation, TCI of remifentanil is paused.

Locations

Country Name City State
Canada CIUSSS de l'Est de l'Ile de Montreal Montreal Quebec

Sponsors (1)

Lead Sponsor Collaborator
Ciusss de L'Est de l'Île de Montréal

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Delta NOL (no unit for the NOL index) To compare the variation of NOL (delta NOL) after tetanic stimulation under general anesthesia based on propofol versus sevoflurane From 1 minute before to 3 minutes after tetanic stimulation for each patient
Secondary Delta Heart Rate (beat per minute) To compare the variation of heart rate after tetanic stimulation under general anesthesia based on propofol versus sevoflurane From 1 minute before to 3 minutes after tetanic stimulation for each patient
Secondary Delta Mean Arterial Blood Pressure (unit: mmHg) To compare the variation of mean arterial blood pressure (MABP) after tetanic stimulation under general anesthesia based on propofol versus sevoflurane From 1 minute before to 3 minutes after tetanic stimulation for each patient
Secondary Delta BIS (no unit for BIS index) To compare the variation of bispectral index (BIS) after tetanic stimulation under general anesthesia based on propofol versus sevoflurane From 1 minute before to 3 minutes after tetanic stimulation for each patient
Secondary Peak value of NOL (no unit) To compare the peak value of NOL after tetanic stimulation under general anesthesia based on propofol versus sevoflurane From 1 minute before to 3 minutes after tetanic stimulation for each patient
Secondary Peak value of Heart Rate (unit: beat per minute) To compare the peak value of heart rate after tetanic stimulation under general anesthesia based on propofol versus sevoflurane From 1 minute before to 3 minutes after tetanic stimulation for each patient
Secondary Peak value of Mean Arterial Blood Pressure (unit: mmHg) To compare the peak value of mean arterial blood pressure (MABP) after tetanic stimulation under general anesthesia based on propofol versus sevoflurane From 1 minute before to 3 minutes after tetanic stimulation for each patient
Secondary Peak value of BIS (no unit) To compare the peak value of bispectral index (BIS) after tetanic stimulation under general anesthesia based on propofol versus sevoflurane From 1 minute before to 3 minutes after tetanic stimulation for each patient
Secondary Area Under the Curve for NOL for Propofol Versus Sevoflurane (no unit) To compare the area under the curve between propofol and sevoflurane between the beginning of stimulation and 3 minutes after stimulation From T0 (start stimulation) to 3 minutes after tetanic stimulation for each patient
Secondary Area Under the Curve for Heart Rate for Propofol Versus Sevoflurane (no unit) To compare the area under the curve between propofol and sevoflurane between the beginning of stimulation and 3 minutes after stimulation From T0 (start stimulation) to 3 minutes after tetanic stimulation for each patient
Secondary Area Under the Curve for Mean Arterial Blood Pressure for Propofol Versus Sevoflurane (no unit) To compare the area under the curve between propofol and sevoflurane between the beginning of stimulation and 3 minutes after stimulation From T0 (start stimulation) to 3 minutes after tetanic stimulation for each patient
Secondary Area Under the Curve for BIS for Propofol Versus Sevoflurane (no unit) To compare the area under the curve between propofol and sevoflurane between the beginning of stimulation and 3 minutes after stimulation From T0 (start stimulation) to 3 minutes after tetanic stimulation for each patient
Secondary Total Dose of Remifentanil (unit: mcg) Total dose of remifentanil in mcg from induction of anesthesia until tracheal extubation Intraoperative
Secondary Total Dose of Propofol (unit: mg) Total dose of propofol in mg from induction of anesthesia until tracheal extubation in Propofol group Intraoperative
Secondary Total Dose of Sevoflurane (unit: mL) Total dose of sevoflurane in mL from induction of anesthesia until tracheal extubation in Sevoflurane group Intraoperative
Secondary Total Dose of Hydromorphone in post-anesthesia care unit (PACU) (unit: mg) Total dose of hydromorphone in mg in post-anesthesia care unit From entrance in post-anesthesia care unit until post-anesthesia care unit discharge, an average of 2 hours
Secondary post-anesthesia care unit (PACU) Pain Scores at Rest (scale from 0 to 10) Pain scores on a scale from 0 to 10 at rest in post-anesthesia care unit From entrance in post-anesthesia care unit until post-anesthesia care unit discharge, an average of 2 hours
Secondary post-anesthesia care unit (PACU) Pain Scores during Cough (scale from 0 to 10) Pain scores on a scale from 0 to 10 during cough effort in post-anesthesia care unit From entrance in post-anesthesia care unit until post-anesthesia care unit discharge, an average of 2 hours
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04580030 - Tricuapid Annular Plane Sistolic Excursion Before General Anesthesia Can Predict Hypotension After Induction
Active, not recruiting NCT04279054 - Decreased Neuraxial Morphine After Cesarean Delivery Early Phase 1
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Recruiting NCT04099693 - A Prospective Randomized Study of General Anesthesia Versus Anesthetist Administered Sedation for ERCP
Terminated NCT02481999 - Pre- and Postoperative EEG-Monitoring for Children Aged From 0,5 to 8 Years
Completed NCT04235894 - An Observer Rating Scale of Facial Expression Can Predict Dreaming in Propofol Anesthesia
Recruiting NCT05525104 - The Effect of DSA on Recovery of Anaesthesia in Children (Het Effect Van DSA op Het Herstel na Anesthesie Bij Kinderen). N/A
Recruiting NCT05024084 - Desflurane and Sevoflurane Minimal Flow Anesthesia on Recovery and Anesthetic Depth Phase 4
Completed NCT04204785 - Noise in the OR at Induction: Patient and Anesthesiologists Perceptions N/A
Completed NCT03277872 - NoL, HR and MABP Responses to Tracheal Intubation Performed With MAC Blade Versus Glidescope N/A
Terminated NCT03940651 - Cardiac and Renal Biomarkers in Arthroplasty Surgery Phase 4
Terminated NCT02529696 - Measuring Sedation in the Intensive Care Unit Using Wireless Accelerometers
Completed NCT05346588 - THRIVE Feasibility Trial Phase 3
Terminated NCT03704285 - Development of pk/pd Model of Propofol in Patients With Severe Burns
Recruiting NCT05259787 - EP Intravenous Anesthesia in Hysteroscopy Phase 4
Completed NCT02894996 - Does the Response to a Mini-fluid Challenge of 3ml/kg in 2 Minutes Predict Fluid Responsiveness for Pediatric Patient? N/A
Completed NCT05386082 - Anesthesia Core Quality Metrics Consensus Delphi Study
Terminated NCT03567928 - Laryngeal Mask in Upper Gastrointestinal Procedures N/A
Recruiting NCT06074471 - Motor Sparing Supraclavicular Block N/A
Completed NCT04163848 - CARbon Impact of aNesthesic Gas